ImMAGE Biotherapeutics develops protein-targeted drug therapies to treat triple-negative breast cancer (TNBC). The company is an affiliate of PepVax, Inc. and was co-founded in 2015; it is based in Washington, DC and Bethesda, MD. Led by COO Mahesh Narayanan and CSO Anton Dormer, PhD., ImMAGE has eight candidates in its pipeline. The firm expects to take these candidates into animal trials this spring. ImMAGE raised an initial seed round of $500K from Coventry International of Hong Kong to fund research of its protein-targeted TNBC therapy. Future funding will be sought to accelerate these candidates through research and development.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2016